Literature DB >> 28780895

The use of pulmonary clearance medications in the acutely ill patient.

Michael F Papacostas1, Peter Luckett1, Susan Hupp1.   

Abstract

INTRODUCTION: Retention of airway secretions occurs in disease, leading to airway plugging, atelectasis, and worsened respiratory mechanics, making airway clearance an important therapeutic target. Areas covered: Many medications designed to enhance clearance of airway secretions are available. We will review the medications available to enhance airway clearance, their mechanisms of action, and the evidence available for their use in acutely ill patients. Expert commentary: In the cystic fibrosis (CF) population, beneficial effects have been shown in pulmonary function with the use of some of these agents. In the non-CF population, there is limited evidence regarding these medications. While some studies have found benefit, the quality of evidence is low, making it difficult to draw conclusions. While certain patients may derive benefit, the general use of these medications in acutely ill patients without CF cannot be recommended at this time.

Entities:  

Keywords:  Airway secretions; hypertonic saline; mucolytics; mucus; pulmonary clearance; sputum

Mesh:

Substances:

Year:  2017        PMID: 28780895     DOI: 10.1080/17476348.2017.1358089

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  2 in total

1.  Use of recombinant human deoxyribonuclease in pediatric intensive care unit - a single-center experience.

Authors:  Daniel Meireles; Sofia Ribeiro Fernandes; Alzira Sarmento; Telma Barbosa; Manuel Ferreira Magalhães; Ana Ramos; Paula Cristina Fernandes
Journal:  Rev Paul Pediatr       Date:  2021-09-01

2.  Mucoactive agent use in adult UK Critical Care Units: a survey of health care professionals' perception, pharmacists' description of practice, and point prevalence of mucoactive use in invasively mechanically ventilated patients.

Authors:  Mark Borthwick; Danny McAuley; John Warburton; Rohan Anand; Judy Bradley; Bronwen Connolly; Bronagh Blackwood; Brenda O'Neill; Marc Chikhani; Paul Dark; Murali Shyamsundar
Journal:  PeerJ       Date:  2020-05-04       Impact factor: 2.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.